Optimizing survival in advanced prostate cancer: Tailoring mCRPC therapies to optimise survival

Bookmark and Share
Sorry, this item is currently unavailable.
Published: 29 Jan 2015
Views: 3902
Prof Karim Fizazi - Institut Gustave Roussy, Paris, France

Prof Fizazi discusses how therapies can be tailored to optimise survival in metastatic castration-resistant prostate cancer at ESMO 2014.

From the same symposium:

Welcome and introduction

Understanding PC heterogeneity to guide treatment choices

CHAARTED: What are the implications for the future?

Learnings from real life practice